News of Note—Aurobindo recalls tainted valsartan APIs; Almac adds peptide capacity


> India’s Aurobindo, which earlier recalled 22 batches of its irbesartan API because it contained N-nitrosodiethylamine (NDEA), is now recalling 80 lots of amlodipine valsartan tablets USP, valsartan HCTZ tablets and valsartan tablets for the same reason. Release

> CDMO Almac Group has added a second line for high throughput GMP peptide manufacturing at its facility in Edinburgh, Scotland, to meet demand from drugmakers working on patient-specific, individualized cancer vaccines. Release

> Cambrex, which makes small molecule generic APIs, has completed its $252 million buyout of Avista Pharma Solutions, a four-facility contract development, manufacturing and testing organization. Release  

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Three former Hikma manufacturing plants in Eatontown, New Jersey, have been acquired by a developer and private investment group, which will sell the equipment and convert the buildings to another use. Release

Suggested Articles

Mylan is recalling a chemo drug and Hospira a commonly used solution because potentially dangerous particulate has been discovered in vials.

Lilly plans a $91 million plant expansion in Indianapolis, and a $7 million tax abatement tied to the project has generated some debate.

Spectrum Pharmaceuticals has pulled its biologics license application for Rolontis because the FDA needs more CMC information.